Eevia Health, a leader in organic nutraceutical ingredients, has announced a repeat sales order valued at KEUR 91 (KSEK 990) from a prominent international nutraceutical company. This order, focusing on Eevia's premium organic bilberry extract, Feno-Myrtillus® 25, highlights the company's growing reputation for delivering high-quality, sustainable ingredients.

The customer, a globally recognized supplier of nutraceutical ingredients, first engaged with Eevia in the summer of 2024. This repeat order is a testament to Eevia's commitment to quality and its ability to compete with established industry players. Stein Ulve, CEO of Eevia Health, expressed his satisfaction, stating, 'This is a sophisticated customer with high standards, and securing this repeat order is a testament to the quality and reliability of our products.'

Furthermore, this order is a strategic step towards achieving Eevia's financial turnaround targets for the first quarter of 2025. As the company continues to strengthen its relationship with key customers, it is well-positioned to expand its market presence globally.

Eevia Health, founded in March 2017, focuses on addressing global health challenges with bioactive compounds sustainably extracted from renewable plant materials. The company's commitment to sustainability and quality is evident in its 100% organically certified plant extracts, which are primarily wild-harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle.

With a modern green-chemistry production facility in Finland, Eevia Health operates with a short value chain and an environmentally friendly carbon footprint. The company's shares are listed on the Spotlight Stock Market in Sweden under the ticker EEVIA.

Given the positive momentum and strategic positioning of Eevia Health in the nutraceutical industry, investors may find it prudent to hold their positions as the company continues to demonstrate growth potential and market expansion.